- Salix's NDA for crofelemer in HIV-associated diarrhea assigned priority review status
- Genentech's BLA for pertuzumab receives priority review status in previously untreated HER2-positive metastatic breast cancer indication
- FDA reviewers questions efficacy of NeurogesX's Qutenza pain patch in proposed new use
- Shire's Vyvanse approved for maintenance treatment in adults with ADHD
- FDA accepts Ziopharm's IND application for oral formulation of Zymafos
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Home :: Psychiatry :: Psychiatry Conferences
AACAP 54th Annual Meeting
October 23-28, 2007 Boston, MA- Childhood ADHD associated with functional deficits in young adulthood, findings suggest
- ADHD, medication use in children associated with emotional strain, poor health status among caregivers
- Stigma associated with ADHD prevalent, may affect receptivity to treatment
- OROS methylphenidate safely treats adult ADHD, trials show
- Dexmethylphenidate extended release at daily doses as high as 30 mg yields improvements in teacher-rated reports of children with ADHD
U.S. Psychiatric & Mental Health Congress 2007
October 11-14, 2007 Orlando, FL- Comorbidities extremely common in children with ADHD; effective patient management requires treating these illnesses as well, experts report
- Methylphenidate transdermal system shows similar efficacy in male, female children with ADHD, although males may face greater risk of adverse events
- Abuse potential with OROS methylphenidate lower than with other methylphenidate formulations
- Stimulant dosing in adults with ADHD lower than effective levels
- Lisdexamfetamine improves parent-rated measures of ADHD
APA 2007 Annual Meeting - ADHD track
May 19-24, 2007 San Diego, CA- Interpatient pharmacokinetic variability lower in patients receiving lisdexamfetamine as compared with mixed amphetamine salts
- OROS methylphenidate shows benefits in patients with ADHD who have comorbid mood, anxiety disorders, concomitant drug therapy in trial
- Extended-release dexmethylphenidate effective in controlling ADHD in children with combined subtype
- Long-term treatment with lisdexamfetamine safe, effective in children with ADHD
- Children, adults, patients with substance use disorders can receive appropriate diagnosis, treatment for ADHD
APA 2007 Annual Meeting - Insomnia track
May 19-24, 2007 San Diego, CA- Patients accurately self-identify middle-of-the-night insomnia; zolpidem improves insomnia in these patients, study data show
- Ramelteon not associated with impairments in middle-of-the-night balance, mobility, memory performance among older adults with primary insomnia, data find
- Ramelteon safe, effective in treatment of insomnia among women in multiple clinical trials
- Eszopiclone does not impair next-day driving ability, cognition relative to placebo, researchers report
- No evidence of dependence with zolpidem CR during long-term treatment, findings show
APSS SLEEP 2007
June 9-14, 2007 Minneapolis, MN- New research offers insight into pathophysiology of insomnia, potential targets for treatment
- Patients with insomnia, comorbid depression have more severe insomnia at baseline relative to patients with primary insomnia, other comorbidities
- Sublingual transmucosal zolpidem effective, well-tolerated among individuals with MOTN insomnia, findings show
- Insomnia represents potentially large financial liability for employers, research indicates
- Eszopiclone demonstrates moderate to strong effect sizes on sleep outcomes relative to placebo in patients with primary insomnia, insomnia with comorbidities
AGS 2007 Annual Scientific Meeting
May 2-6, 2007 Seattle, WA- IMPACT depression model twice as effective as usual care, successfully implemented in some organizations
- Insomnia affects many older adults, needs to be treated
- Once-daily duloxetine 60 mg effective treatment for MDD-related anxiety in older patients, study suggests
- MDD not adequately recognized, treated in older adults, experts say
- Clinicians should seek individualized treatment plans for geriatric patients with multiple comorbidities, according to experts
- AstraZeneca, Targacept's depression drug candidate misses goal in second Phase III study
- Alexza's inhaled antipsychotic may cause respiratory failure, FDA reviewers warn
- Actavis launches first generic version of Novartis' Ritalin LA
- Alkermes commences Phase III study of schizophrenia drug candidate
- FDA advisory panel supports approval of Alexza's inhaled antipsychotic
- Mental health disorders increasingly affecting workers' productivity, well-being, OECD report indicates
- Health system-related variables seem to influence likelihood of screening mammography among women with intellectual disabilities, findings suggest
- Merck dissolves AD agreement with Acumen, signs PI3K inhibitor agreement with Exelixis
- FDA advisory panel supports approval of Alexza's inhaled antipsychotic
- Obesity associated with increased health costs in middle-aged women, even after adjusting for co-occurring depression, data suggest
